Prior studies on the use of febuxostat by a person with chronic respiratory failure who was also untreated with anoxic lung infections have shown that the drug is effective against the objects of infection, the cells that cause inflammation, such as collagen and lung tissue cells, in blocked blood vessels.
FenogPRO is a porphyrin-containing drug extracted from seaweed.
The drug is well-tolerated and effective against anoxic lung infections.
The Silva Laboratories (University of Goias in Brazil) is the manufacturer of the drug.
The work represents the completion of an extensive three-year clinical trial in which over 20 patients were treated with fenogPRO either alone or in combination with two common anoxic drugs, spermicides and triamteremic acid (TM/TT), in clinical trials.
We believe that this data holds promise for the use of febuxostat in acute lung infections, particularly anoxic lung infections.
Category: Children’s Health
Reducing headline-costs for cancer drugs by 30 percent
Surgical staging is a cornerstone of cancer care and saves money that could be spent evaluating poorer candidates before deciding on the best course of treatment, according to a new study can open the door to patients.
Continue readingRussia scientists confirm coronavirus vaccine as country lacking rules, controlsruff
Russia has thrown out one of the country’s earlier attempts at regulating a government agency, saying that it lacked the resources and staff it would need as it is already fully equipped with controlling a paralyzingly contagious virus. Russia, a country of 11.5 million, has reported 378 coronavirus cases and just over 2,400 deaths, making […]
Continue reading